엠에스바이오 Stock: price and insider trades · South Korea
6 insiders bought shares over the last 90 days, the latest by 김성포, filed 29 Oct 2026.
Cluster: 6 buyers in 30 days엠에스바이오: what insiders have been doing
엠에스바이오 is a listed company. Its directors and officers file their transactions with DART (FSS). From 31 October 2025 to 31 October 2026, the disclosure feed for 엠에스바이오 logged 6 filings by 6 insiders.
The flow runs one way only: 6 insiders bought (6 purchases) and nobody sold on the market. The totals do not cover 6 filings with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Those buying include 2 board members and 1 chief executive.
For context, the typical company on the same exchange (median of 2,655 companies) published 7 filings over the same period, against 6 filings here. The full history, which starts in 2026, counts 6 purchases against no sales.
The most recent open-market purchase was published on 29 October 2026, 10 days ago.
Source: insider filings from DART (FSS). Past trades are no guide to future returns.
Who traded when
BuySaleTransparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 663,660 sharesShareKRXDART:20261029000355Canonical exit: 27 Jan 2027 (T+90)
- Other0DART
- Other0DART
- 6,946,860 sharesShareKRXDART:20261029000364Canonical exit: 27 Jan 2027 (T+90)
- Other0DART
- 638,660 sharesShareKRXDART:20261029000325Canonical exit: 27 Jan 2027 (T+90)
- 512,610 sharesShareKRXDART:20261029000282Canonical exit: 27 Jan 2027 (T+90)
- 772,975 sharesShareKRXDART:20261029000399Canonical exit: 27 Jan 2027 (T+90)
- Other0DART
- 2,236,312 sharesShareKRXDART:20261028000219Canonical exit: 26 Jan 2027 (T+90)
10 of 10 declarations
About 엠에스바이오
엠에스바이오 is a company listed on the XKRX, specializing in the biopharmaceutical sector. It focuses on developing innovative solutions for disease treatment.